ONCE-DAILY SUSTAINED-RELEASE MATRIX TABLETS OF LOSARTAN POTASSIUM: FORMULATION AND IN VITRO EVALUATION

Journal Title: International Journal of Medical and Clinical Research - Year 2010, Vol 1, Issue 1

Abstract

Objective of the present study was to develop hydrophilic polymer and hydrophobic polymer based matrix Losartan potassium sustained release tablet which can release the drug up to time of 24 hrs in predetermined rate. Formulation of Losartan potassium matrix tablet was prepared by the polymer combination in order to get required theoretical release profile. Influence of hydrophilic and hydrophobic polymer on Losartan potassium was studied. Formulated tablet were also characterized by physical and chemical parameters. In vitro release profile was check for 24 hrs to evaluate the SR matrix tablet of Losartan potassium. Losartan potassium (LP) is a potent, highly specific Angiotensin II type 1 (AT1) receptor antagonist with antihypertensive activity. It is readily absorbed from the gastrointestinal tract with oral bioavailability of about 33% and a plasma elimination half-life ranging from 1.5 to 2.5 hr. Administration of LP in a sustained release dosage would be more desirable for antihypertensive effects by maintaining the plasma concentrations of the drug well above the therapeutic concentration. From in vitro dissolution profile, Batch B4 was prepared with blend of HPMC K4M (67.2 mg), HPMC K200M(90mg) and Eudragit RSPO(112.5 mg), where drug release was about 94-98%. Batch B4 showed highest similarity factor values (f2 = 67.76).

Authors and Affiliations

B. G. Prajapati, K. R. Patel

Keywords

Related Articles

THYROID FUNCTION TESTS IN NIGERIAN HIV SERO- POSITIVE PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)

Background: Recent studies suggest that the prevalence of hypothyroidism among human immunodeficiency virus (HIV) people who were on treatment with highly active antiretroviral therapy (HAART) was higher than that in tre...

MYOCARDIAL DEPRESSANT ACTIVITY OF A NEWLY SYNTHESISED DIHYDROPYRIMIDINE DERIVATIVE 5-ACYL-6-METHYL-4-PHENYL-2-S-ETHYL-1, 4-DIHYDROPYRIMIDINE (BK-vi) IN COMPARISON WITH NIFEDIPINE

Objective- To investigate the myocardial depressant activity of a newly synthesised dihydropyrimidine derivative 5-acyl-6-methyl-4-phenyl-2 -S-ethyl-1,4-dihydropyrimidine (BK - vi) and comparing with nifedipine on Isolat...

PRESENCE OF RENAL ARTERY VARIATIONS AND ITS SURGICAL CORRELATION

The paired renal arteries arise from the aorta just below the origin of the superior mesenteric artery and takes 20% of cardiac output. These are end arteries with no anastomoses. Variations in the number and arrangement...

STUDY OF BIOLOGICAL EFFECTS WHEN EXPOSURE TO He-Ne LASER AND UVC RADIATION ON HEAD SPERM ABNORMALITIES IN MICE

In vitro, He-Ne laser show a modifying response of cells to ionizing radiations. So there is a need to show the effect of He-Ne laser (632.8 nm), Ultraviolet radiation UVC (250 nm) and He-Ne laser pre and post irradiatio...

PROTEINS OF CLASSICAL AND LECTIN PATHWAY OF THE COMPLEMENT SYSTEM INVOLVED IN THE PATHOGENESIS OF RHEUMATIC HEART DISEASE

Background: Rheumatic heart disease is an inflammatory disease which predominantly affects the valvular endocardium culminating in crippling valve deformities. Inorder to find out the role of complement proteins in induc...

Download PDF file
  • EP ID EP170014
  • DOI 10.9735/0976-5530.1.1.1-7
  • Views 129
  • Downloads 0

How To Cite

B. G. Prajapati, K. R. Patel (2010). ONCE-DAILY SUSTAINED-RELEASE MATRIX TABLETS OF LOSARTAN POTASSIUM: FORMULATION AND IN VITRO EVALUATION. International Journal of Medical and Clinical Research, 1(1), 1-5. https://europub.co.uk/articles/-A-170014